Printer Friendly

EPITOPE ANNOUNCES GLOBAL MARKETING/MANUFACTURING PACTS AT SHAREHOLDERS' MEETING

 PORTLAND, Ore., Feb. 22 /PRNewswire/ -- At its annual shareholders' meeting today, Epitope Inc. (AMEX: EPT) announced several new developments related to its OraSure(R) oral specimen collection device. The company has established a joint venture in the People's Republic of China, has agreed to supply OraSure to an additional U.S. insurance testing laboratory, and has appointed a company to manufacture OraSure in the United Kingdom.
 "We are pleased to announce these important milestones which represent progress in enhancing the market penetration of OraSure," said Adolph J. Ferro, president and chief executive officer.
 -- Chinese Joint Venture
 Epitope and China National Biological Products Corp. (China National), a marketing arm of the Chinese government, have formed a joint venture, Beijing Epitope Biotech Co., (Beijing Epitope) in the People's Republic of China. The company is 50-percent owned by Epitope and 50-percent owned by China National. Beijing Epitope will manufacture and distribute OraSure within the People's Republic of China. The joint venture will also manufacture and market family- planning products from reagents currently under development at Epitope. Epitope will market the venture's products outside of China.
 "The establishment of this cooperative program with China provides an exciting opportunity to place Epitope's products in a position to reach the most populated country in the world," said Kevin M. Crowley, vice president of medical products. He applauded the Chinese government for its efforts to bring new technology to its people.
 -- Insurance Testing
 Clinical Reference Laboratory Inc. (CRL), Lenexa, Kansas, has agreed to purchase Epitope's OraSure device for its total requirements of devices for collection of oral specimens in the continental United States. Shipments may commence upon FDA approval of OraSure for HIV-1 testing. CRL becomes the second insurance testing laboratory to enter into an OraSure supply agreement. In August 1992, Epitope announced a similar agreement with Home Office Reference Laboratory.
 -- United Kingdom Manufacturing
 The Chiltern Division of Owen Mumford Ltd. has been engaged to manufacture OraSure in the United Kingdom for distribution to Europe and other markets outside the United States. Mumford has over 30 years of experience in manufacturing specialty medical products.
 "By adding Chinese and British production sites to our existing U.S. manufacturing alliance with MML Diagnostics Packaging Inc. of Troutdale, Ore., we have moved a long way toward our goal of global manufacturing capability," said Ferro.
 Epitope Inc. is an Oregon corporation utilizing biotechnology to develop diagnostic tests for AIDS and other indications, therapeutic antimicrobial drugs and, through its agricultural unit, Agritope Inc., superior new plant varieties.
 -0- 2/22/93
 /CONTACT: Mary Hagen of Epitope, 503-641-6115; or Shari Annes of Annes Associates, 415-728-5400, for Epitope/
 (EPT)


CO: Epitope Inc.; China National Biological Products Corp.; Clinical
 Reference Laboratory Inc.; Owen Mumford Ltd. ST: Oregon, Kansas IN: MTC SU: JVN


SW-JH -- SE002 -- 8847 02/22/93 09:49 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:466
Previous Article:IDEC PHARMACEUTICALS SIGNIFICANTLY EXPANDS LYMPHOMA CLINICAL PROGRAM
Next Article:MCI ANNOUNCES FIVE-MINUTE 800 GUARDIAN -- NO FAULT GUARANTEE IS INDUSTRY FIRST --
Topics:


Related Articles
EPITOPE'S ORASURE PREMARKET APPROVAL APPLICATION SCHEDULED FOR REVIEW BY FDA ADVISORY PANEL
EXERCISE PRICE SET FOR EPITOPE WARRANTS TO BE ISSUED FOR CLASS ACTION SETTLEMENT
EPITOPE AND KIPKE SETTLE LAWSUIT
EPITOPE REPORTS FIRST QUARTER OPERATING RESULTS
EPITOPE, INC. REPORTS SECOND-QUARTER OPERATING RESULTS
SMITHKLINE BEECHAM'S CONSUMER HEALTH CARE DIVISION REACHES AGREEMENT WITH EPITOPE, INC. TO ENTER THE DIAGNOSTIC MARKET
EPITOPE ANNOUNCES COMPLETION OF DUE DILIGENCE PERIOD FOR AGREEMENT WITH SMITHKLINE BEECHAM
Epitope Announces First Quarter Operating Results
Record Date Set For Agritope Spin-Off
Epitope Announces Five-Year Exclusive Distribution Agreement of OraSure(R) In the UK

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters